関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 2,4-Dichloropyridine | HCID 33515 | — |
| 反応物 | 2-Methyl-2H-pyrazol-3-ylamine | HCID 136927 | — |
| 試薬 | Sodium t-butoxide | HCID 23676156 | — |
| 触媒 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 触媒 | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| 溶媒 | 1,4-Dioxane | HCID 31275 | — |
| 生成物 | 4-chloro-N-(2-methylpyrazol-3-yl)pyridin-2-amine | HCID 121439713 | 56.88% |
反応手順
TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (251 mg, 0.27 mmol) was added in one portion to 2,4-dichloropyridine (1000mg, 6.76 mmol), 1,3-dimethyl-1H-pyrazol-5-amine (826 mg, 7.43 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (461 mg, 0.80 mmol) and sodium tert-butoxide (974 mg, 10.14 mmol) in 1,4-dioxane (60 mL) warmed to 130ºC over a period of 10 minutes under nitrogen. The resulting mixture was stirred at 130°C for 20 hours. The reaction mixture was evaporated to dryness and redissolved in DCM (150 mL). Solids were filtered off by suction and the filtrate subsequently washed with water (100 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 4% MeOH in DCM. Pure fractions were evaporated to dryness to afford 4-chloro-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine (802 mg, 56.9 %) as a yellow oil which crystallised on standing.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-3c8e64b916074a0fa79f8b674402d3e9 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|